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Palytoxin (PTX), a highly toxic and sugar-containing substance isolated from Palythoa tuberculosa, 
caused K+ release from rabbit red blood cells. Cardiac glycosides, such as ouabain, convallatoxin, 
cymarin, digoxin and digitoxin, inhibited the PTX-induced K+ release. Their corresponding aglycones did 
not inhibit the K+ release, but antagonized the inhibitory effect of the glycosides. All these cardiotonic 
steroids equally inhibited the activity of (Na++K+)-ATPase prepared from hog cerebral cortex. These 
results suggest hat the sugar moiety of the cardiac glycosides is important for the inhibitory effect on the 
K+ release induced by PTX and that the inhibition is not related to their inhibitory potency on the 
(Na+ + K+)-ATPase activity. 
Palytoxin Cardiac glycoside K+ release 
1. INTRODUCTION 
Palytoxin (PTX; CizsH22sN3054), isolated from 
marine coelenterates of some zoanthid species 
(genus Palythoa), is the most potent animal toxin 
known to date [l]. The stereochemistry of PTX 
has recently been determined [2,3]. PTX is unique- 
ly distinct from the molecules in terms of 
magnitude of molecular size, structural complexi- 
ty, etc. It consists of a long partially unsaturated 
aliphatic chain, interspaced with 5 sugar moieties. 
The biological actions of PTX have been exten- 
sively studied (for references see [4]). At concen- 
trations of a few nanomolar, it causes depolariza- 
tion of cardiac, smooth and skeletal muscles and 
nerve tissues. It also causes release of K+ from red 
blood cells and smooth muscles. It has been 
reported that the effect of PTX is inhibited by oua- 
bain in smooth muscles [5] and red blood cells 
[6,7]. Authors in [6,7] have suggested that PTX in- 
creases the ion permeability by altering the state of 
(Na+ + K+)-ATPase or its environment. 
Here, to improve the understanding of the in- 
teraction of PTX with (Na+ +K+)-ATPase, we 
Red blood cell (Na+ + K+)-A TPase 
have investigated the effects of various cardiac 
glycosides and aglycones on the effects of PTX in 
red blood cells in relation to their inhibitory poten- 
cy on (Na+ + K+)-ATPase activity. 
2. MATERIALS AND METHODS 
Red blood cells from rabbit heparinized 
(30 IU/ml) blood were washed 3 times in 5 vols 
physiological salt solution (PSS) (NaCl, 
136.9 mM; CaCl2, 1.0 mM; MgCl2, 1 .O mM; 
glucose, 5.5 mM; Hepes, 10 mM; pH 7.3) by cen- 
trifugation at 3000-4000 rpm for 5 min. The buf- 
fy coat was removed by aspiration. Packed cells 
were resuspended in PSS (200000-300000 cells/ 
ml) and stored at 4°C. Under these conditions, no 
apparent K+ loss was observed for at least 5 h. The 
loss of K+ after the addition of PTX at 37°C was 
measured using a K+-selective lectrode (Philips, 
IS 561 K) at 37°C. Maximum release of K+ was 
achieved by adding saponin (lOpg/ml) for 10 min. 
(Na+ + K+)-ATPase from hog cerebral cortex 
prepared as in [8] was purchased from Sigma. The 
specific activity of (Na+ + K+)-ATPase was 
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0.6-0.7 pmol Pi released/mg protein per min at 
37°C. The enzyme preparation was incubated in a 
solution containing NaCl (100 mM), KC1 
(20 mM), MgClz (5 mM), ATP (5 mM) and 
Tris-HCl(50 mM) at pH 7.4. The final volume of 
the solution was 0.5 ml. The enzyme preparation 
was preincubated in the absence of ATP for 5 min 
and then the reaction was started by the addition 
of ATP. The amount of Pi liberated during the 
15 min incubation was determined as in [9]. The 
activity of (Na+ +K+)-ATPase was calculated by 
the difference between the quantity of Pi liberated 
in the presence and absence of Na+ and K+. 
PTX isolated from Palythoa tuberculosa was 
kindly donated by Dr Y. Hirata (Meijo University, 
Nagoya). The toxin was dissolved in distilled water 
to prepare a 10e4 M stock solution, which was kept 
frozen at -20°C. Other drugs used were ouabain 
(Merck), ouabagenin, convallatoxin, cymarin, 
strophanthidin, digoxin, digoxigenin (all from 
Sigma), digitoxin, digitoxigenin (both from 
Aldrich), saponin (ICN), melittin (Sigma), and 
nigericin (Calbiochem). The water-insoluble drugs 
were dissolved in ethanol, methanol or dimethyl- 
formamide, or a combination of these. The final 
volume of the organic solvents was less than 0.2%. 
The solvents alone did not affect the K+ release. 
For the experiments on (Na+ + K+)-ATPase, 
water-insoluble drugs were dissolved in acetone or 
dimethylformamide and diluted with the incuba- 
tion solution. 
3. RESULTS AND DISCUSSION 
PTX at concentrations above 10-i’ M produced 
rapid loss of K+ from rabbit red blood cells in a 
concentration-dependent manner (EDSO = 5 x 
lo-” M). Ouabain (ouabagenin monorham- 
noside) at a concentration as low as 10V7 M in- 
hibited the PTX-induced K+ release (fig.1). The 
K+ release due to nigericin (10V6 M), saponin 
(10 pug/ml) and melittin ( 10m6 M) was not affected 
by ouabain (2 x 10m5 M), suggesting that the in- 
hibition by ouabain is specifically directed against 
the action of PTX. Other monoglycosides, such as 
convallatoxin (strophanthidin monorhamnoside) 
and cymarin (strophanthidin monocymaroside) 
more potently inhibited the K+ release due to PTX 
(10m9 M). Triglycosides, such as digoxin (digox- 
0 5 10 
TIME (min) 
Fig.1. Inhibitory effect of various concentrations of 
ouabain on K+ release induced by PTX. Red blood cells 
were incubated with PTX (2.5 x 10e9 M) and various 
concentrations of ouabain: (0) 0, (0) lo-’ M, (m) 5 x 
lo-’ M, (0) 10e6 M). Ordinate, K+ remaining in red 
blood cells (To). Abscissa, time (min). 
Table 1 
Inhibitory effect of various cardiotonic steroids on K+ 
release induced by PTX (A) and (Na+ +K+)-ATPase 
activity (B) 
(A) ZCSO for 
K+ release 
(M) 
(B) ZCSO for 
(Na+ + K+)- 
ATPase (M) 
Ouabain 
Convallatoxin 
Cymarin 
Digoxin 
Digitoxin 
Ouabagenin 
Strophanthidin 
Digoxigenin 
Digitoxigenin 
2.3 x 1O-6 
9.0 x lo-’ 
4.2 x lo-’ 
9.0 x 1o-5 
8.8 x 1O-5 
* 
* 
* 
* 
7.6 x lo-’ 
8.4 x lo-’ 
3.4 x lo-’ 
5.9 x lo-’ 
1.5 x lo-’ 
n.d. 
8.0 x lo-’ 
3.4 x lo-’ 
2.1 x lo-’ 
Red blood cells were incubated with PTX (10e9 M) and 
various concentrations of cardiotonic steroids for 
30 min. (Na+ + K+)-ATPase was incubated with 
cardiotonic steroids and ATP (5 mM) for 15 min. Note 
that ZCso value for aglycones could not be calculated (*). 
n.d., not determined 
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igenin tridigitoxoside) and digitoxin (digitoxigenin 
tridigitoxoside), were less potent than ouabain. 
ZCSO values of the cardiac glycosides for the action 
of PTX are summarized in table 1. In contrast, 
ouabagenin and strophanthidin at 10m5 M pro- 
duced no inhibition of the PTX-induced K+ 
release. Digoxigenin and digitoxigenin (low5 M) 
also failed to inhibit the K+ release. These results 
suggest hat the sugar moiety of cardiac glycosides 
is important for the inhibitory effect on the PTX- 
induced K+ release. 
Fig.2 shows the effect of cymarin (10-6-10-4 M) 
on PTX-induced K+ release in the absence or 
presence of its aglycone, strophanthidin (10m5 M). 
In the presence of strophanthidin, the dose- 
response curve for the inhibitory effect of cymarin 
was shifted to the right. These results suggest hat 
the binding of strophanthidin inhibits the binding 
of cymarin to the red blood cell membrane and 
thus the effect of cymarin is decreased. 
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Fig.2. Antagonism by strophanthidin of the inhibitory 
effect of cymarin on PTX-induced K+ release. Red 
blood cells were preincubated with various 
concentrations of cymarin (1O-8-lO-4 M) and 
strophanthidin (10e5 M) for 5 min. PTX (10m9 M) was 
then added for 20 min to induce K+ release. (0) 
Cymarin alone; (0) strophanthidin + cymarin. 
Ordinate, amount of K+ release (‘-70); abscissa, time 
(min). 
Finally, the effect of these cardiotonic steroids 
on (Na+ + K+)-ATPase activity was investigated. 
Ouabain, convallatoxin, cymarin, digoxin and 
digitoxin, and their corresponding aglycones in- 
hibited the activity of (Na+ + K+)-ATPase 
prepared from hog cerebral cortex with ZCSO values 
of 10-7-10-6 M (table 1). These results suggest 
that the inhibitory effect of cardiac glycosides on 
PTX-induced K+ release is not related to their in- 
hibition of the (Na+ + K+)-ATPase. 
It has been suggested that the binding sites for 
PTX and ouabain are not identical but share some 
common sites [6]. One possibility is that the 
binding sites for PTX and ouabain overlap at the 
sugar binding site on (Nat + K+)-ATPase or the 
neighbouring structure, since the PTX molecule 
also contains sugar moieties. The other possibility 
is that cardiac glycoside induces allosteric transi- 
tions in (Naf +K+)-ATPase and decreases the 
binding affinity for PTX, and that the sugar moie- 
ty is essential for this transition. 
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